Monographie - Daptomycin

Última actualização :
28/04/2024

Daptomycin

Estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Cubicin	Alemanha, Argentina, Austria, Canadá, Chilli, Colômbia, Dinamarca, Espanha, Estados Unidos de América, Finlandia, França, Gran-bretanha, Grècia, Hungria, Índia, Irlanda, Islandia, Itália, Japón, Luxemburgo, Malásia, México, Noruega, Nova Zelândia, Países Baixos, Polonia, Portugal, Romènia, Suècia, Suicia, Turquia, Venezuela
Daptomicina	Espanha
Daptomicine	Gran-bretanha

Bibliografía : Daptomycin

	Tipo	Publicação
1937	Jornal	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
2247	Jornal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Jornal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2271	Laboratório	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
3122	Jornal	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3218	Jornal	Peyro Saint Paul L, Albessard F, Gaillard C, Debruyn D, Ryckelynck J Ph, Antoine Coquerel, Lobbedez T Daptomycin Compatibility in Peritoneal Dialysis Solutions Perit Dial Int 2011 ; 31: 492?495.
3439	Jornal	Parra M.A, Campanero M.A, S?daba B, Irigoyen A, Garc?a-L?pez L,Fernandez-Reyes M.J, Ramon Azanza J. Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions. Perit Dial Int 2013 ; 33:458-461
3665	Jornal	Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3976	Jornal	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Jornal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4074	Jornal	Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. Stability of daptomycin reconstituted vials and infusion solutions. EJHP 2018 ; 25: 107-110.
4145	Jornal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Jornal	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4380	Laboratório	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4528	Jornal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

Mentions Légales